Organogenesis Holdings stock (US68620V1026): shares steady as investors look beyond recent earnings
01.06.2026 - 17:10:12 | ad-hoc-news.de
Organogenesis Holdings shares traded on the Nasdaq in the United States were broadly stable on 06/01/2026, with the stock moving roughly in line with the US healthcare small-cap segment as investors continued to weigh the implications of its most recent quarterly update and the broader reimbursement environment for advanced wound care products, according to exchange data as of late May 2026.
The stock, which is listed on Nasdaq under the ticker ORGO, has seen trading volumes normalize in recent sessions following volatility around its latest earnings release, while market participants track developments in Organogenesis Holdings' core United States wound care and surgical biologics markets as reflected in recent regulatory filings and company commentary on its investor relations page at Organogenesis Holdings investor relations as of 05/2026.
The shares remain primarily a US-listed equity story, with liquidity centered on Nasdaq, although the stock can also be accessed by German retail investors via secondary venues such as Tradegate in euros based on the underlying US listing price and prevailing EUR/USD exchange rates, according to German trading venue data as of 05/2026.
The stock traded at a mid-single-digit USD price level on 05/31/2026 on Nasdaq, according to Nasdaq quote data as of 05/31/2026, placing Organogenesis Holdings firmly in the US small-cap segment of the healthcare sector.
As of: 01.06.2026
By the editorial team - specialized in equity coverage.
At a glance
- Name: ORGO
- Sector/industry: Regenerative medicine and advanced wound care
- Headquarters/country: Canton, United States
- Core markets: United States hospital and outpatient wound care centers, with selective international distribution
- Key revenue drivers: Advanced wound care products, surgical and sports medicine biologics, and related tissue-based regenerative solutions
- Home exchange/listing venue: Nasdaq (ORGO)
- Trading currency: USD
Organogenesis Holdings: core business model
Organogenesis Holdings focuses on developing and commercializing regenerative medicine products, with revenue primarily generated from advanced wound care and surgical biologics used by hospitals and specialized wound care centers, particularly in the United States.
What banks and research houses say about Organogenesis Holdings
No verified analyst coverage was identified at the time of publication.
Read more
Additional news and developments on the stock can be explored via the linked overview pages.
Sentiment and reactions on Organogenesis Holdings
Investor discussion around Organogenesis Holdings on social platforms typically focuses on revenue trends in advanced wound care, reimbursement decisions in the United States, and the company’s pipeline of regenerative medicine products.
Conclusion
Organogenesis Holdings shares on Nasdaq remain closely tied to developments in the US advanced wound care and regenerative medicine markets, with investors monitoring earnings execution, reimbursement frameworks and product uptake in key hospital and outpatient settings. The limited visible analyst coverage at the time of publication means market participants may focus more heavily on company guidance, official filings and trading dynamics when updating their own views on the stock.
Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.
